Phase 3 N=35 Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Recurrent or Progressive Glioblastoma
Primary: Local Tumor Control — 14; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma
Adult Glioblastoma
Primary: Number of Participants Who Received Treatment Recommendations Within 35 Days of Surgery — 15 Participants
Phase 2 N=33 Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Arm 1: Progression Free Survival (PFS) — 0; 0 Participants
Phase 2 N=68 Bevacizumab Beyond Progression (BBP)
Malignant Glioma · Grade 4 Malignant Glioma · Glioblastoma
Primary: Overall Survival — 17.8 months
Phase 2 N=35 Pazopanib in Treating Patients With Recurrent Glioblastoma
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: 6 Months Progression-free Survival — 3 percent
Phase 2 N=55 Bevacizumab in Treating Patients With Recurrent or Progressive Glioma
Brain and Central Nervous System Tumors
Primary: Safety of Treatment — 1; 1; 5; 1 participants
Phase 2 N=56 Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Overall Survival — 5.7 months — p=0.4
Phase 2 N=59 Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
Glioblastoma · Gliosarcoma
Primary: 6 Month Progression-Free Survival (PFS) — 41; 44 percentage of participants
Phase 2 N=25 Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
Glioblastoma · Astrocytoma · Oligodendroglioma
Primary: Progression-free Survival at 6-months — 17.3 percentage of participants
Phase 2 N=45 Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: PFS-6 — 1; 8 Participants
Phase 2 N=33 Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Gliomas
Primary: Overall Response Rate — 9 percent
Phase 2 N=62 Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Primary: ORR — 0; 0; 0; 0 percentage of patients
Phase 2 N=56 Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
Adult Brain Tumor · Adult Giant Cell Glioblastoma · Adult Glioblastoma
Primary: Maximum Tolerated Dose of Tandutinib Defined by Dose Limiting Toxicities (Phase 1) — 600 mg BID
Phase 2 N=158 A Study in Recurrent Glioblastoma (GB)
Glioblastoma
Primary: Overall Survival (OS) — 8.0; 6.7; 7.5 Months
Phase 2 N=58 Dose-Intense Temozolomide in Recurrent Glioblastoma
Glioblastoma · Gliosarcoma
Primary: 6 Month Progression Free Survival — 11 percentage of evaluable participants
Phase 2 N=56 A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: Progression-free Survival Rate at 6 Months — 15.4 Percentage of participants
Phase 2 N=103 Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Proportion of Successes (Patients Alive and Progression-free) — 15.2; 26.7; 10 percentage of participants
Phase 2 N=123 Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
Adult Glioblastoma · Adult Gliosarcoma · Recurrent Adult Brain Neoplasm
Primary: Count/Percentage of Patients Progression-free at 6 Months for Bevacizumab and Irinotecan Hydrochloride Arm — 22 Participants
Phase 2 N=37 BIBF 1120 for Recurrent High-Grade Gliomas
Glioblastoma · Gliosarcoma · Anaplastic Astrocytoma
Primary: 6-Month Progression Free Survival — 0 percentage of participants
Phase 2 N=88 Bevacizumab for Recurrent Malignant Glioma
Recurrent High-Grade Gliomas · Malignant Gliomas
Primary: Percentage of Participants With Progression Free Survival at 6 Months. — 20.9; 29 Percentage of participants
Phase 2 N=80 Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
Adult Glioblastoma Multiforme
Primary: Percentage of Participants Who Achieved Progression-Free Survival Rate at 6 Months (PFS-6) — 12.5; 7.5 percentage of participants
Phase 2 N=44 Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Progression-free Survival at 6 Months — 0; 29 percentage of patients
Phase 2 N=58 Everolimus in Treating Patients With Recurrent Low-Grade Glioma
Adult Diffuse Astrocytoma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: Progression-free Survival at 6 Months. — 39; 6 Participants
Phase 2 N=31 Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
Glioblastoma Multiforme · Brain Tumor
Primary: Progression-free Survival (PFS) — 91.3 percentage of participants
Phase 2 N=151 A Study in Subjects With Recurrent Malignant Glioma
Glioma
Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants
Phase 2 N=32 A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: Progression-Free Survival (PFS) - Percentage of Participants With an Event — 96.88 percentage of participants
Phase 1 N=20 Ketogenic Diet for Recurrent Glioblastoma
Recurrent Glioblastoma
Primary: Applicability as Measured by Discontinuation of Study Treatment Due to Intolerability — 15 percent of participants
Phase 2 N=182 Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Overall Survival — 25.1; 21.6 percentage of participants — p=0.46
Phase 2 N=66 BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
IDH1 Mutation · IDH2 Mutation · Recurrent Glioblastoma
Primary: Participants With Dose Limiting Toxicity (DLT) Rate Less Than or Equal to 33% (Dose Level 1) — 0; 7 Participants
Phase 2 N=7 Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
Glioma
Primary: Progression-free Survival